ARWR
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$58.98
+1.65%Year over year
Reported trailing growth
- Revenue
- +12.2%
- EBITDA
- —
- EBIT
- —
- EPS
- -76.4%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -56.9%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +50.5%
- EBITDA
- +129.4%
- EBIT
- +116.4%
- Net income
- +99.7%
- EPS
- +99.8%
- Free cash flow
- +126.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026